Skip to content
★ Sign in to follow
유니

유니온바이오메트릭스 Stock: price and insider trades · South Korea

KR·Mcap ₩31BHealth Care

No insider purchase over the last 90 days. The latest, by 신요식, was filed 14 Feb 2024.

유니온바이오메트릭스: what insiders have been doing

This page follows insider dealings at 유니온바이오메트릭스 as filed with DART (FSS), a company from the Health Care sector. Over the twelve months to 1 November 2026, 2 filings were filed, from 1 insider.

The filings describe grants, exercises and other transfers rather than trades on the open market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.

There has been no open-market purchase by an insider of 유니온바이오메트릭스 for at least a year.

Compared with its exchange (2,655 companies, median 7 filings), a count of 2 filings is below the norm. Our records for 유니온바이오메트릭스 go back to 2021, with 6 purchases and 1 sale on the open market in total.

Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and UCB. Source: insider filings from DART (FSS). Past trades are no guide to future returns.

Insider Decl.
17
Thresholds
n/a
Buy Volume
€5M
6 ops. · all time
Sell Volume
€291,944
1 ops. · all time

Since the insiders bought

  • Filed 14 Feb 2024 · 1000 days ago · €24k
    -10.0%
    Entry ₩3,085 · Close at T+365 ₩2,775
  • Filed 27 Oct 2023 · 1110 days ago · €1,911
    -1.3%
    Entry ₩2,680 · Close at T+365 ₩2,645

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 17,491 of 26,911 companies
41.8
score / 100
Value
38
Quality
46
FCF yld-43%
Earn yld6.9%
EV/EBITDA14.2x
ROE·
Gross mgn38%
Net mgn3.9%
Debt/EBITDA3.3x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

₩2,590
Analyst consensus
·
Income statement
Revenue₩51.3B
Gross profit₩19.3B38% margin
EBITDA₩2.7B5% margin
Net income₩2B3.9% margin
Balance sheet & cash
Market cap₩31B
Total debt₩8.8B
Free Cash Flow-₩12.7B
Last declaration on 19 March 2026
Declarations20 total
  • Other
    Other(filed)
    0DART
  • Other
    Other(filed)
    0DART
  • Other
    Other(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ▼
    대량보유자Executives
    €292kest.0DART
    117,545 sharesKRXDART:20240405003189
  • ▲
    Executives
    35M KRW10DART
    10,700 shares@ ₩3,232.5234100.0% of flowShareKRXDART:20240214001708
    Canonical exit: 10 Jul 2023 (T+90)
  • ▲
    대량보유자Executives
    €152kest.0DART
    69,111 sharesKRXDART:20240214001817
    Canonical exit: 5 May 2024 (T+90)
  • ●
    Executives
    Executives
    0DART
  • ▲
    Executives
    3M KRW10DART
    1,000 shares@ ₩2,730.00100.0% of flowShareKRXDART:20231027000407
    Canonical exit: 21 Jan 2024 (T+90)
  • ▲
    Related company / holdingExecutives
    €1.5Mest.0DART
    705,358 sharesKRXDART:20230825000147
    Canonical exit: 21 Nov 2023 (T+90)
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ▲
    Related company / holdingExecutives(filed)
    €1.5Mest.0DART
    705,358 sharesKRXDART:20220711000303
    Canonical exit: 9 Oct 2022 (T+90)
  • ▲
    Related company / holdingExecutives(filed)
    €1.9Mest.0DART
    705,358 sharesKRXDART:20220510000266
    Canonical exit: 8 Aug 2022 (T+90)
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART

20 of 20 declarations

About 유니온바이오메트릭스

유니온바이오메트릭스 is a company operating in the health and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative biometric solutions.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations